Shanghai Junshi Biosciences Deal History & Licensing Activity
Shanghai Junshi Biosciences is a biotech headquartered in China. Over the past three years, Shanghai Junshi Biosciences has been involved in 2 licensing and acquisition transactions, with a primary focus on Antibodies (4 deals). The company currently has 31 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
2
Active Trials
31
Top Modality
Antibodies
Focus Area
Solid Tumors
Shanghai Junshi Biosciences Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Shanghai Junshi Biosciences in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| roconkibart | Fosun Wanbang | Antibodies | Phase 3 | license | Jul 2, 2026 |
| Roconkibart (JS005) | Fosun Wanbang (Jiangsu) Pharmaceutical Group | Antibodies | Phase 2 | license | Jun 30, 2026 |
Shanghai Junshi Biosciences Pipeline Focus
Therapeutic areas and modalities where Shanghai Junshi Biosciences is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Shanghai Junshi Biosciences Clinical Pipeline
Shanghai Junshi Biosciences has 31 active clinical trials across 5 development phases.
5
Phase 1
1
Phase 1/2
13
Phase 2
1
Phase 2/3
11
Phase 3
See How Your Asset Matches Shanghai Junshi Biosciences's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Shanghai Junshi Biosciences Licensing & Deal Activity
Shanghai Junshi Biosciences is a biotech company based in China that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Shanghai Junshi Biosciences ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Shanghai Junshi Biosciences include Solid Tumors (25 deals and trials), Immunology (4 deals and trials), Hematological Malignancies (4 deals and trials), and Metabolic (1 deal and trial). In terms of modality, Shanghai Junshi Biosciences has shown particular interest in antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Shanghai Junshi Biosciences and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Shanghai Junshi Biosciences's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.